Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors

Ana M Pajor1, Cesar A de Oliveira2, Kun Song2

  • 1University of California San Diego (A.M.P.), Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California; Cardiovascular, Metabolic and Endocrine Disease Research Unit (K.S., K.H., D.M.E.), Pfizer Worldwide Research and Development, Cambridge, Massachusetts; Center of Chemistry Innovation and Excellence (C.A.O., V.S.), Pfizer Worldwide Research and Development, Groton, Connecticut apajor@ucsd.edu.

Molecular Pharmacology
|September 30, 2016
PubMed

Insights

Researchers investigated the Na+/citrate transporter (NaCT) and its inhibitors. Key residues affecting citrate transport and drug binding were identified, paving the way for improved metabolic disease therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The Na+/citrate transporter (NaCT, SLC13A5) is crucial for metabolic regulation and a target for treating metabolic diseases.
  • Citrate acts as a signaling molecule influencing lipid and glucose metabolism.
  • Previous research identified two high-affinity NaCT inhibitors, PF-06649298 and PF-06678419.

Purpose of the Study:

  • To elucidate the molecular mechanisms of NaCT inhibition and transport.
  • To identify specific amino acid residues involved in inhibitor binding and substrate transport.
  • To provide a foundation for designing novel SLC13 inhibitors.

Main Methods:

  • Molecular modeling of human NaCT (hNaCT).
  • Site-directed mutagenesis of hNaCT residues.
  • Transport assays to characterize citrate uptake.
  • Cell-surface biotinylation to assess protein localization.

Main Results:

  • Residues G228, V231, V232, and G409 near the citrate binding site impact both transport and inhibitor binding.
  • Residue V231 differentiates the inhibitory effects of PF-06649298 and PF-06678419.
  • Residues Q77 and T86, outside the putative citrate site, also influence NaCT inhibition.

Conclusions:

  • Specific residues within and outside the citrate binding pocket are critical for NaCT function and inhibition.
  • Understanding these interactions advances knowledge of NaCT transport mechanisms.
  • These findings support the rational design of NaCT-targeting drugs for metabolic disorders.

Related Concept Videos

Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
12.9K
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
140.1K
The Significance of Membrane Transport01:44

The Significance of Membrane Transport

The transport of solutes across the cell membrane is essential for metabolic processes, like maintaining cell size and volume, generating the action potential, exchanging nutrients and gases, etc. Membrane transport can be either passive or active. It can be simple diffusion, facilitated, or mediated transport aided by transport proteins such as transporters and channels.
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
43.7K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
90
Active Transport01:14

Active Transport

Active transport is a critical biological process that allows cells to move solutes against an electrochemical gradient. This process requires direct energy input and is characterized by its selectivity, saturability, and susceptibility to competitive inhibition.
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
2.5K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.5K